Cargando…

Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays

The SARS‐CoV‐2 main protease (M(pro)) cleaves along the two viral polypeptides to release non‐structural proteins required for viral replication. M(Pro) is an attractive target for antiviral therapies to combat the coronavirus‐2019 disease. Here, we used native mass spectrometry to characterize the...

Descripción completa

Detalles Bibliográficos
Autores principales: El‐Baba, Tarick J., Lutomski, Corinne A., Kantsadi, Anastassia L., Malla, Tika R., John, Tobias, Mikhailov, Victor, Bolla, Jani R., Schofield, Christopher J., Zitzmann, Nicole, Vakonakis, Ioannis, Robinson, Carol V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461284/
https://www.ncbi.nlm.nih.gov/pubmed/32841477
http://dx.doi.org/10.1002/anie.202010316
_version_ 1783576736318881792
author El‐Baba, Tarick J.
Lutomski, Corinne A.
Kantsadi, Anastassia L.
Malla, Tika R.
John, Tobias
Mikhailov, Victor
Bolla, Jani R.
Schofield, Christopher J.
Zitzmann, Nicole
Vakonakis, Ioannis
Robinson, Carol V.
author_facet El‐Baba, Tarick J.
Lutomski, Corinne A.
Kantsadi, Anastassia L.
Malla, Tika R.
John, Tobias
Mikhailov, Victor
Bolla, Jani R.
Schofield, Christopher J.
Zitzmann, Nicole
Vakonakis, Ioannis
Robinson, Carol V.
author_sort El‐Baba, Tarick J.
collection PubMed
description The SARS‐CoV‐2 main protease (M(pro)) cleaves along the two viral polypeptides to release non‐structural proteins required for viral replication. M(Pro) is an attractive target for antiviral therapies to combat the coronavirus‐2019 disease. Here, we used native mass spectrometry to characterize the functional unit of M(pro). Analysis of the monomer/dimer equilibria reveals a dissociation constant of K (d)=0.14±0.03 μM, indicating M(Pro) has a strong preference to dimerize in solution. We characterized substrate turnover rates by following temporal changes in the enzyme‐substrate complexes, and screened small molecules, that bind distant from the active site, for their ability to modulate activity. These compounds, including one proposed to disrupt the dimer, slow the rate of substrate processing by ≈35 %. This information, together with analysis of the x‐ray crystal structures, provides a starting point for the development of more potent molecules that allosterically regulate M(Pro) activity.
format Online
Article
Text
id pubmed-7461284
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74612842020-09-02 Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays El‐Baba, Tarick J. Lutomski, Corinne A. Kantsadi, Anastassia L. Malla, Tika R. John, Tobias Mikhailov, Victor Bolla, Jani R. Schofield, Christopher J. Zitzmann, Nicole Vakonakis, Ioannis Robinson, Carol V. Angew Chem Int Ed Engl Communications The SARS‐CoV‐2 main protease (M(pro)) cleaves along the two viral polypeptides to release non‐structural proteins required for viral replication. M(Pro) is an attractive target for antiviral therapies to combat the coronavirus‐2019 disease. Here, we used native mass spectrometry to characterize the functional unit of M(pro). Analysis of the monomer/dimer equilibria reveals a dissociation constant of K (d)=0.14±0.03 μM, indicating M(Pro) has a strong preference to dimerize in solution. We characterized substrate turnover rates by following temporal changes in the enzyme‐substrate complexes, and screened small molecules, that bind distant from the active site, for their ability to modulate activity. These compounds, including one proposed to disrupt the dimer, slow the rate of substrate processing by ≈35 %. This information, together with analysis of the x‐ray crystal structures, provides a starting point for the development of more potent molecules that allosterically regulate M(Pro) activity. John Wiley and Sons Inc. 2020-10-15 2020-12-21 /pmc/articles/PMC7461284/ /pubmed/32841477 http://dx.doi.org/10.1002/anie.202010316 Text en © 2020 The Authors. Published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Communications
El‐Baba, Tarick J.
Lutomski, Corinne A.
Kantsadi, Anastassia L.
Malla, Tika R.
John, Tobias
Mikhailov, Victor
Bolla, Jani R.
Schofield, Christopher J.
Zitzmann, Nicole
Vakonakis, Ioannis
Robinson, Carol V.
Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
title Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
title_full Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
title_fullStr Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
title_full_unstemmed Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
title_short Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
title_sort allosteric inhibition of the sars‐cov‐2 main protease: insights from mass spectrometry based assays
topic Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461284/
https://www.ncbi.nlm.nih.gov/pubmed/32841477
http://dx.doi.org/10.1002/anie.202010316
work_keys_str_mv AT elbabatarickj allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT lutomskicorinnea allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT kantsadianastassial allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT mallatikar allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT johntobias allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT mikhailovvictor allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT bollajanir allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT schofieldchristopherj allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT zitzmannnicole allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT vakonakisioannis allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays
AT robinsoncarolv allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays